Edition:
United States

Almirall SA (ALM.MC)

ALM.MC on Madrid SE C.A.T.S.

8.56EUR
12 Dec 2017
Change (% chg)

€0.32 (+3.88%)
Prev Close
€8.24
Open
€8.32
Day's High
€8.65
Day's Low
€8.20
Volume
739,184
Avg. Vol
491,797
52-wk High
€16.88
52-wk Low
€7.28

Chart for

About

Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating... (more)

Overall

Beta: 0.36
Market Cap(Mil.): €1,425.12
Shares Outstanding(Mil.): 172.95
Dividend: 0.19
Yield (%): 2.31

Financials

  Industry Sector
P/E (TTM): -- 31.83 15.71
EPS (TTM): -- -- --
ROI: -- 15.03 31.93
ROE: -- 16.54 16.16

BRIEF-Almirall And Athenex Announces Partnership For Treatment Of Actinic Keratosis

* ALMIRALL AND ATHENEX ANNOUNCE STRATEGIC PARTNERSHIP FOR THE TREATMENT OF ACTINIC KERATOSIS

Dec 11 2017

BRIEF-Almirall Announces Positive Top-Line Results From ASCENT Trial For Tudorza‍​

* ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE IV ASCENT TRIAL FOR TUDORZA‍​

Dec 04 2017

Spanish stocks - Factors to watch on Friday

The following Spanish stocks may be affected by newspaper reports and other factors on Friday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy:

Nov 17 2017

BRIEF-Almirall announces achievement of $80 mln sales-related milestones from agreement with Astrazeneca‍​

* ANNOUNCES ACHIEVEMENT OF $80 MILLION SALES-RELATED MILESTONES FROM AGREEMENT WITH ASTRAZENECA‍​ Source text for Eikon:

Nov 17 2017

Spain's Almirall warns of delay in approval for psoriasis drug

Spanish pharma company Almirall said on Tuesday it expects the launch of psoriasis treatment drug, Tildrakizumab, in Europe to get delayed by at least six months due to regulatory hurdles.

Nov 14 2017

Spain's Almirall warns of delay in approval for psoriasis drug

Nov 14 Spanish pharma company Almirall said on Tuesday it expects the launch of psoriasis treatment drug, Tildrakizumab, in Europe to get delayed by at least six months due to regulatory hurdles.

Nov 14 2017

BRIEF-Almirall 9-month net result turns to loss of 99.7 mln euros YoY

* 9-MONTH EBITDA 100.1 MILLION EUROS VERSUS 183.8 MILLION EUROS YEAR AGO

Nov 06 2017

BRIEF-Almirall ends phase III research for nail psoriasis product in Europe

* TERMINATES ITS RESEARCH ACTIVITIES FOR P3073 PROGRAM (NAIL PSORIASIS) IN EUROPE IN PHASE III OF DEVELOPMENT ‍​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Oct 31 2017

BRIEF-Almirall: study confirms efficacy of Sativex in treating multiple sclerosis spasticity

* SAYS STUDY CONFIRMS EFFICACY AND TOLERABILITY OF SATIVEX IN TREATMENT OF MULTIPLE SCLEROSIS SPASTICITY RESISTANT PATIENTS Source text: http://bit.ly/2yPWT4P Further company coverage: (Gdynia Newsroom)

Oct 27 2017

BRIEF-Almirall ends research for two products in US

* SAYS DECIDED TO TERMINATE ITS RESEARCH ACTIVITIES FOR P3058 (ONYCHOMYCOSIS) AND P3073 (NAIL PSORIASIS) IN THE US

Sep 29 2017

Earnings vs. Estimates